GSK and Daiichi Sankyo to form joint venture (5504Y)

TIDMGSK

RNS Number : 5504Y

GlaxoSmithKline PLC

01 March 2012

Issued: Thursday 1(st) March 2012, London UK and Philadelphia, US

GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan

GlaxoSmithKline (GSK) today announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vaccines company in Japan.

The JV will hold the development and commercial rights for already existing preventative vaccines from both parent companies. It will supply globally recommended vaccines to help protect people of all ages in Japan including Human Papillomavirus (HPV) vaccine, Rotavirus vaccine, Seasonal flu vaccine, Mumps vaccine, Diphtheria Pertussis (DTP) vaccine, and Measles Rubella (MR) vaccine. The business will be expanded in the future as new vaccines in the JV development pipeline are approved.

Both companies will sell their respective vaccines into the JV at agreed upon prices and expect sales synergies from the JV. The companies will have an equal stake in the joint venture and will split the JV's profits 50/50 with a portion going toward funding ongoing capital needs of the JV. There will be a minimal total cash investment of 100 million Yen (approximately GBP800,000) split equally between the two companies to cover the start up capital requirements of the JV.

Christophe Weber, President Designate of GlaxoSmithKline Vaccines, commented, "This collaboration marks another step in our strategy to build our presence in key growth markets and will create the first and largest company dedicated solely to vaccines in Japan. We are very pleased to be partnering with Daiichi Sankyo, a highly regarded company and an established leader in Japan. Both companies have strong track records in commercialisation and, in combination, will create further significant economies of scale in the development and distribution of vaccines in the Japanese market."

Completion of the transaction is expected in the 3(rd) quarter of 2012, subject to local regulatory approvals.

V A Whyte

Company Secretary

1 March 2011

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

 
 GlaxoSmithKline Enquiries: 
 UK Media enquiries:           David Mawdsley       [phone]    (London) 
                                                     5502 
                               Stephen Rea          [phone]    (London) 
                                                     5502 
                               Sarah Spencer        [phone]    (London) 
                                                     5502 
                               David Daley          [phone]    (London) 
                                                     5502 
 
 US Media enquiries:           Kevin Colgan         [phone]    (North Carolina) 
                               Melinda Stubbee      [phone]    (North Carolina) 
                               Sarah Alspach        [phone]    (Washington, 
                                                                        DC) 
                               Jennifer Armstrong   [phone]    (Philadelphia) 
 
 Analyst/Investor enquiries:   Sally Ferguson       [phone]    (London) 
                                                     5543 
                               Tom Curry            + 1 215 751 5419   (Philadelphia) 
                               Gary Davies          + 44 (0) 20 8047   (London) 
                                                     5503 
                               Jeff McLaughlin      + 1 215 751 7002   (Philadelphia) 
                               Ziba Shamsi          + 44 (0) 20 8047   (London) 
                                                     3289 
 
 
 Cautionary statement regarding forward-looking statements 
  Under the safe harbor provisions of the U.S. Private Securities 
  Litigation Reform Act of 1995, GSK cautions investors that 
  any forward-looking statements or projections made by GSK, 
  including those made in this announcement, are subject 
  to risks and uncertainties that may cause actual results 
  to differ materially from those projected. Factors that 
  may affect GSK' s operations are described under 'Risk 
  Factors' in the 'Business Review' in the company' s Annual 
  Report on Form 20-F for 2010. 
 
 
 Registered in England & Wales: 
  No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

JVESSSEDFFESEID